© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
People with HIV had low rates of complications similar to those of HIV-negative patients.
The results from an innovative, “virtual” clinical trial were presented at the 2019 ASCO Annual Meeting.
RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
ASCO and Friends of Cancer Research proposed new eligibility guidelines in 2017.
Researchers believe specially designed cancer care programs could prevent Black patients from being lost to care.
New study tests ability of natural language processing to search lung cancer patients’ records for treatable mutations.
Multipronged approach eliminated treatment gaps between black and white patients and improved overall treatment rates.
Lung cancer advocate Don Stranathan takes on the No. 1 cancer killer.
Researchers say the biomarker could help noninvasively diagnose precancerous lung growths and distinguish them from benign nodules.
Checkpoint inhibitor immunotherapy, alone or in combination with chemotherapy, shows promise for advanced non-small-cell lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
